Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0008329
UniProt IDP42338
Primary gene name(s)PIK3CB
Synonym gene name(s)PIK3C1
Protein namePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
Protein functionPhosphoinositide-3-kinase, PI3K that phosphorylates PtdIns, Phosphatidylinositol, PtdIns4P, Phosphatidylinositol 4-phosphate and PtdIns(4,5P2, Phosphatidylinositol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-trisphosphate, PIP3. PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors, GPCRs ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins, ITGA2B/ ITGB3 and ITAM, immunoreceptor tyrosine-based activation motif-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2, thrombin and thromboxane A2, TXA2. Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P, Phosphatidylinositol 3-phosphate and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors. {ECO:0000269|PubMed:18594509, ECO:0000269|PubMed:18755892, ECO:0000269|PubMed:21030680, ECO:0000269|PubMed:21383062}.
Subcellular locationCytoplasm {ECO:0000269|PubMed:21383062}. Nucleus {ECO:0000269|PubMed:21383062}. Note=Interaction with PIK3R2 is required for nuclear localization and export.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P42338
Gene Ontology
(Biological Process)
Complete annatation
activation of MAPK activity [GO:0000187];
angiogenesis involved in wound healing [GO:0060055];
autophagy [GO:0006914];
cell migration [GO:0016477];
cellular calcium ion homeostasis [GO:0006874];
chemotaxis [GO:0006935];
embryonic cleavage [GO:0040016];
endothelial cell proliferation [GO:0001935];
Fc-epsilon receptor signaling pathway [GO:0038095];
Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096];
G-protein coupled receptor signaling pathway [GO:0007186];
homophilic cell adhesion via plasma membrane adhesion molecules [GO:0007156];
leukocyte migration [GO:0050900];
phosphatidylinositol 3-kinase signaling [GO:0014065];
phosphatidylinositol biosynthetic process [GO:0006661];
phosphatidylinositol-mediated signaling [GO:0048015];
phosphorylation [GO:0016310];
platelet activation [GO:0030168];
platelet aggregation [GO:0070527];
positive regulation of autophagy [GO:0010508];
positive regulation of gene expression [GO:0010628];
regulation of cell-matrix adhesion [GO:0001952];
regulation of clathrin-dependent endocytosis [GO:2000369];
regulation of phosphatidylinositol 3-kinase signaling [GO:0014066];
signal transduction [GO:0007165];
T cell receptor signaling pathway [GO:0050852];
transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169];
vascular endothelial growth factor receptor signaling pathway [GO:0048010]
Gene Ontology
(Molecular Function)
Complete annatation
1-phosphatidylinositol-3-kinase activity [GO:0016303];
1-phosphatidylinositol-4-phosphate 3-kinase activity [GO:0035005];
ATP binding [GO:0005524];
phosphatidylinositol 3-kinase activity [GO:0035004];
phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
intercellular bridge [GO:0045171];
nucleolus [GO:0005730];
nucleus [GO:0005634];
phosphatidylinositol 3-kinase complex [GO:0005942];
plasma membrane [GO:0005886]
Protein-protein interaction111309
Phylogenetic treeP42338
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.7347886932737790.02882306731453070.0629322425850509
AZA vs. DISU0.2060481304795760.4192145862491980.911342924190573
AZA vs. IL7-0.1009429824717320.6025262597332790.999311006273513
AZA vs. SAHA-0.155986910381240.524728941350810.835690680187985
DISU vs. CD30.9289078948666230.01145866722009910.0324475212835724
DISU vs. IL7-0.3160285476732920.2127529299051860.592676373745025
DISU vs. SAHA-0.3611138261016850.2179558048922870.593033387891616
DMSO vs. AZA-0.05097986363070540.7633592027137151
DMSO vs. CD30.6734656208466560.04015964683734250.079974233919969
DMSO vs. DISU-0.2583761410793590.2939648722101080.806677299793064
DMSO vs. IL7-0.04314673902881270.8119795196647740.962538241700332
DMSO vs. SAHA-0.1122812024663540.6356062167490260.882166384918945
HIV vs. Mock in Activation0.1949199937363750.7890432556784370.999983755607037
HIV vs. Mock in Latency0.004988586899051490.9760753970443020.999834320637052
IL7 vs. CD30.6417219707699170.05027838798849490.110232166130994
SAHA vs. CD30.5539693340725980.1240664682717710.206994002633096
SAHA vs. IL7-0.05863436810227220.8105701759750350.918122801707429
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
0.3126 0.04129

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.0609319 0.749336
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
212688_at 1.32 No downregulated in CD8+ cells

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB05241 XL765 investigational unknown unknown
DB00201 Caffeine approved unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Nef interacts with 11289809
12526811
12584329
17632570
20702582
23215766
Tat activates 17157319
20019835
21029719
21765914
8798481
9394803
9708406
11156964
11994280
17157319
Envelope surface glycoprotein gp120 modulated by 16524887
Envelope surface glycoprotein gp160; precursor inhibits 9808187
Nef involves 26075907
Envelope surface glycoprotein gp160; precursor activates 9341793
Envelope surface glycoprotein gp120 mediated by 16081599
Tat interacts with 11154208
14602571
23077641
9446795
Nef complexes with 18854243
Vpr involves 26270987
26270987
Tat inhibited by 12077252
Envelope surface glycoprotein gp120 inhibited by 20818790
Envelope surface glycoprotein gp120 relocalizes 18453587
Tat induces phosphorylation of 23301033
Nef downregulates 8636073
9247029
10208934
Tat regulated by 24073214
Envelope surface glycoprotein gp120 activates 12551992
12960231
2004121318453587
23251686
Envelope surface glycoprotein gp120 regulated by 15689238
Nef activates 25104021
Nef upregulates 10985305

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00562 Inositol phosphate metabolism - Homo sapiens (human)
hsa01521 EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human)
hsa01522 Endocrine resistance - Homo sapiens (human)
hsa01524 Platinum drug resistance - Homo sapiens (human)
hsa04012 ErbB signaling pathway - Homo sapiens (human)
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04015 Rap1 signaling pathway - Homo sapiens (human)
hsa04022 cGMP-PKG signaling pathway - Homo sapiens (human)
hsa04024 cAMP signaling pathway - Homo sapiens (human)
hsa04062 Chemokine signaling pathway - Homo sapiens (human)
hsa04066 HIF-1 signaling pathway - Homo sapiens (human)
hsa04068 FoxO signaling pathway - Homo sapiens (human)
hsa04070 Phosphatidylinositol signaling system - Homo sapiens (human)
hsa04071 Sphingolipid signaling pathway - Homo sapiens (human)
hsa04072 Phospholipase D signaling pathway - Homo sapiens (human)
hsa04150 mTOR signaling pathway - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04152 AMPK signaling pathway - Homo sapiens (human)
hsa04210 Apoptosis - Homo sapiens (human)
hsa04211 Longevity regulating pathway - Homo sapiens (human)
hsa04213 Longevity regulating pathway - multiple species - Homo sapiens (human)
hsa04261 Adrenergic signaling in cardiomyocytes - Homo sapiens (human)
hsa04360 Axon guidance - Homo sapiens (human)
hsa04370 VEGF signaling pathway - Homo sapiens (human)
hsa04380 Osteoclast differentiation - Homo sapiens (human)
hsa04510 Focal adhesion - Homo sapiens (human)
hsa04550 Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human)
hsa04611 Platelet activation - Homo sapiens (human)
hsa04620 Toll-like receptor signaling pathway - Homo sapiens (human)
hsa04630 Jak-STAT signaling pathway - Homo sapiens (human)
hsa04650 Natural killer cell mediated cytotoxicity - Homo sapiens (human)
hsa04660 T cell receptor signaling pathway - Homo sapiens (human)
hsa04662 B cell receptor signaling pathway - Homo sapiens (human)
hsa04664 Fc epsilon RI signaling pathway - Homo sapiens (human)
hsa04666 Fc gamma R-mediated phagocytosis - Homo sapiens (human)
hsa04668 TNF signaling pathway - Homo sapiens (human)
hsa04670 Leukocyte transendothelial migration - Homo sapiens (human)
hsa04722 Neurotrophin signaling pathway - Homo sapiens (human)
hsa04725 Cholinergic synapse - Homo sapiens (human)
hsa04750 Inflammatory mediator regulation of TRP channels - Homo sapiens (human)
hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human)
hsa04910 Insulin signaling pathway - Homo sapiens (human)
hsa04914 Progesterone-mediated oocyte maturation - Homo sapiens (human)
hsa04915 Estrogen signaling pathway - Homo sapiens (human)
hsa04917 Prolactin signaling pathway - Homo sapiens (human)
hsa04919 Thyroid hormone signaling pathway - Homo sapiens (human)
hsa04921 Oxytocin signaling pathway - Homo sapiens (human)
hsa04923 Regulation of lipolysis in adipocytes - Homo sapiens (human)
hsa04930 Type II diabetes mellitus - Homo sapiens (human)
hsa04931 Insulin resistance - Homo sapiens (human)
hsa04932 Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human)
hsa04933 AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human)
hsa04960 Aldosterone-regulated sodium reabsorption - Homo sapiens (human)
hsa04973 Carbohydrate digestion and absorption - Homo sapiens (human)
hsa05100 Bacterial invasion of epithelial cells - Homo sapiens (human)
hsa05142 Chagas disease (American trypanosomiasis) - Homo sapiens (human)
hsa05145 Toxoplasmosis - Homo sapiens (human)
hsa05146 Amoebiasis - Homo sapiens (human)
hsa05160 Hepatitis C - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
hsa05205 Proteoglycans in cancer - Homo sapiens (human)
hsa05210 Colorectal cancer - Homo sapiens (human)
hsa05211 Renal cell carcinoma - Homo sapiens (human)
hsa05212 Pancreatic cancer - Homo sapiens (human)
hsa05213 Endometrial cancer - Homo sapiens (human)
hsa05214 Glioma - Homo sapiens (human)
hsa05215 Prostate cancer - Homo sapiens (human)
hsa05218 Melanoma - Homo sapiens (human)
hsa05220 Chronic myeloid leukemia - Homo sapiens (human)
hsa05221 Acute myeloid leukemia - Homo sapiens (human)
hsa05222 Small cell lung cancer - Homo sapiens (human)
hsa05223 Non-small cell lung cancer - Homo sapiens (human)
hsa05224 Breast cancer - Homo sapiens (human)
hsa05230 Central carbon metabolism in cancer - Homo sapiens (human)
hsa05231 Choline metabolism in cancer - Homo sapiens (human)
Menu